Potential for noninvasive brain tumor treatmentJune 17, 2009DURHAM, N.C. -- Duke University engineers have taken a first step toward a minimally invasive treatment of brain tumors by combining chemotherapy with heat administered from the end of a catheter. The proof-of-concept study demonstrated that it should be technically possible to treat brain tumors without the side effects associated with the traditional approaches of surgery, systemic chemotherapy or radiation. The bioengineers designed and built an ultrasound catheter that can fit into large blood vessels of the brain and perform two essential functions: provide real-time moving 3-D images and generate localized temperature increases. The researchers envision using this system in conjunction with chemotherapy drugs encased in heat-sensitive microbubbles called liposomes. "Physicians would inject drug-carrying liposomes into a patient's bloodstream, and then insert a catheter via a blood vessel to the site of the brain tumor," said Carl Herickhoff, fourth-year graduate student at Duke's Pratt School of Engineering and first author of a paper appearing in the journal Ultrasonic Imaging. "The catheter would use ultrasound to first image the tumor, and then direct a higher-power beam to generate heat at the site, melting the liposome shells and releasing the chemotherapy directly to the tumor. "The temperature increase would be about four degrees Celsius - enough to melt the liposome, but not enough to damage surrounding tissue," Herickhoff said. "No one has tried this approach before in the brain." The American Cancer Society estimates that more than 21,000 new brain tumor cases were diagnosed in 2008, with more than 13,000 patients dying. This represents about two percent of all cancer deaths. The researchers said that a minimally invasive approach to treating this cancer would be preferable to the conventional methods, which have drawbacks and side effects of their own. "Surgery is invasive, and chemotherapy that is injected or taken orally affects the whole body and has difficulty crossing the blood-brain barrier in sufficient concentrations," Herickhoff said. The blood-brain barrier restricts the passage into the brain of any foreign matter not needed by the neural tissue. In a series of experiments in animal models and simulated tissues, the researchers demonstrated that they could build a catheter thin enough to be placed in one of the brain's main blood vessels that was capable of serving the dual purpose of visualization and heating. "Taken as a whole, the results of these experiments, in particular the clarity of the images and ability to increase temperature with the same catheter, lead us to believe that the ultimate creation of a practical intracranial ultrasound catheter is possible," said Stephen Smith, director of the Duke University Ultrasound Transducer Group and senior member of the research team. "There are some design issues of the catheter itself that we feel can be overcome with little difficulty." Advances in ultrasound technology have made these latest experiments possible, the researchers said, by generating detailed, 3-D moving images in real-time. The Duke laboratory has a long track record of modifying traditional 2-D ultrasound - like that used to image babies in utero - into the more advanced 3-D scans. After inventing the technique in 1991, the team also has shown its utility in developing specialized catheters and endoscopes for real-time imaging of tissues throughout the body. Much of the liposome research was carried out at Duke by David Needham, professor of mechanical engineering and materials science, and Mark Dewhirst, professor of radiation oncology. Duke University |
|||||||||||||||||||||
| Related Chemotherapy Current Events and Chemotherapy News Articles New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. For young boys with cancer, testicular tissue banking may be option to preserve fertility For parents of children with cancer, the hopeful news is that pediatric survival rates have steadily improved for decades. Among the bad news-treatments that enable survival often cause infertility. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Chemo-radiation before prostate removal may prevent cancer recurrence Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. PMH finding may help some tonsil cancer patients avoid chemotherapy Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. More Chemotherapy Current Events and Chemotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||